索拉非尼对肝癌晚期患者血清肝癌标志物的影响

Effect of sorafenib on serum hepatoma marker in patients with advanced hepatocellular carcinoma

目的探讨索拉非尼对肝癌晚期患者血清肝癌标志物的影响及临床意义。方法选取2014年2月~2014年12月于河北省邢台市第二医院肿瘤科已确诊为肝癌晚期的患者101例,根据随机数字表法分为2组：对照组50例,临床常规治疗;实验组51例,在对照组治疗基础上加用索拉非尼。比较2组患者的生存时间、不良反应、血管内皮生长因子（vascular endothelial growth factor,VEGF）、结缔组织生长因子（connective tissue growth factor,CTGF）、缺氧诱导因子-1α（hypoxia inducible factor 1α,HIF-1α）和骨桥蛋白（osteopontin,OPN）水平的变化,对比分析2种治疗方法的临床疗效。结果经随访,实验组生存期高于对照组（P〈0.05）;与对照组相比,实验组血清VEGF、CTGF、HIF-1α、OPN、AFP、CEA及CA199水平均较低（P〈0.05,P〈0.01）。2组总不良反应发生率比较差异无统计学意义。结论索拉非尼能有效延长肝癌患者生存期,降低血清VEGF、CTGF、HIF-1α和OPN水平。

Objective To investigate effect of sorafenib on serum hepatoma marker in patients with advanced hepatocellular carcinoma. Methods 101 patients with advanced hepatocellular carcinoma were selected, and divided into two groups.50 cases in control group were treated with routine clinical treatment, and 51 cases in experimental group were treated with sorafenib on the basis of control group.The survival time, adverse reactions, VEGF, CTGF, HIF-1 and OPN levels were compared after the treatment.Results The survival time of experimental group was higher than control group （P〈0.05）.Compared with control group, the serum levels of VEGF、CTGF,HIF-1, OPN,AFP, CEA, and CA199 in experiment group were lower （P〈0.05,P 〈0.01）.There were no significant differences of total adverse reactions between experimental group and control group. Conclusion Sorafenib can effectively prolong survival time of patients with advanced hepatocellular carcinoma, reduce serum VEGF, CTGF, HIF-1 alpha and OPN levels.